WHO puts neglected tropical disease supply chains under tighter coordination
WHO and partner agencies used three consecutive meetings in Geneva to press for something the neglected tropical disease response has long needed: a supply chain that behaves like a health system rather than a sequence of disconnected handoffs. Ministries of health, pharmaceutical donors, implementing partners and technical support platforms gathered on 22–25 September 2026 to tighten forecasting, improve data visibility, reduce delays and align medicine delivery with national systems.
For neglected tropical disease programmes, the logistics problem is not peripheral. These campaigns depend on donated medicines moving through forecasting, ordering, customs, storage, distribution and eventual use with little room for slippage. When any link slows, treatment schedules and preventive campaigns can unravel long before a patient ever reaches a clinic or outreach post.
The week centered on the NTD Supply Chain Forum, the Supply Chain Technical Support Mechanism and the Global Coordination and Stewardship Committee. Each group examined the same basic pressure points from a different angle: how to make medicine flows more predictable, how to detect bottlenecks early, and how to assign accountability before stock sits idle, expires or becomes trapped at a port.
Forecasting failures, customs delays and weak visibility dominated the forum agenda
The NTD Supply Chain Forum brought ministries of health, WHO, nongovernmental organizations, logistics providers and technical partners into the same room to review persistent problems across the medicine pipeline. Forecasting, order and shipment timelines, customs clearance, inventory visibility and medicine utilization all came under scrutiny.
Those are not abstract management terms. In NTD programmes, poor forecasting can trigger either shortages or excess stock, both of which can damage treatment coverage. Customs delays can leave donated products stranded for weeks or months, while weak inventory visibility makes it difficult to know whether medicines have reached the intended district, facility or campaign team.
Reliable data ran through the discussion as the central organizing principle. Participants stressed clearer coordination from programme planning and medicine requests through shipment, delivery and use. They also examined ways to align NTD medicine management with national health and logistics information systems instead of building parallel structures that fragment responsibility and obscure the real location of supplies.
A direct clinical consequence follows from that approach. When NTD delivery is embedded within national systems, the same stock records, transport routes and reporting channels can support routine care, campaign delivery and accountability checks. The model reduces duplication and gives ministries a clearer line of sight from central warehouse to patient-facing distribution.
Country systems showed measurable gains in customs clearance and standard operating procedures
The Supply Chain Technical Support Mechanism meeting moved from system design to practical country experience. Eight priority countries have now developed validated NTD supply chain standard operating procedures, up from three countries when the initiative began. In supply chain work, formal procedures are more than paperwork; they define who acts, when escalation happens and which data trigger intervention.
Uganda reported reducing customs-clearance time from approximately 90 days to 20 days. The Democratic Republic of the Congo reported a 63% reduction in clearance time and no demurrage during the period discussed. Those gains matter because customs is one of the most common choke points for donated medicines. Every day saved at the border lowers the risk of missed campaigns, storage crowding and quality loss from prolonged transit.
Country leadership also appeared to be strengthening. Kenya, Ethiopia and the Democratic Republic of the Congo became the first to lead rotating country coordination meetings, with other countries expected to follow. This matters for a programme area that has often depended heavily on external coordination. Rotating leadership shifts practical problem-solving closer to the places where delays, paperwork and transport barriers actually occur.
Reverse logistics and integration with central medical stores also featured prominently. Unused products, returns and redistribution require the same discipline as initial shipment. Without that discipline, inventory can disappear into administrative blind spots, leaving planners with a false sense of available supply.
Forecasts out to 2030 offer visibility, but only if they are kept current
Multi-year forecasting drew particular attention because four countries presented projections extending toward 2030. Long-range forecasts create a bigger planning horizon for treatment needs, inventory and funding, but they only remain useful when tested against changing programme conditions.
The participants focused on assumptions about treatment needs, available inventory, programme changes and funding. Those assumptions are vulnerable to shifts in population coverage, epidemiology, campaign timing and procurement constraints. A forecast that is not regularly refreshed can harden into false certainty, which is exactly how supply chains accumulate shortages at one end and excess stock at the other.
The meetings therefore treated forecasting as a living process rather than a one-time exercise. Reliable supply chain data, regular review and active decision-making were presented as the only way to keep projected demand aligned with what ministries can actually deliver.
Stewardship now extends beyond medicine movement to accountability, expiry and transition planning
The Global Coordination and Stewardship Committee widened the lens further, placing systemic risk and accountability at the center of the conversation. Participants discussed how supply chain performance and bottlenecks are monitored and followed through to resolution, with a proposed evidence and performance framework designed to draw on NTDeliver, Joint Application Package metrics, country feedback and working-group outputs.
The aim is not merely surveillance for its own sake. The framework would improve visibility of exceptions, responsible owners, timelines and decisions required. In a supply chain built around donated medicines, that kind of accountability determines whether a delay is resolved quickly or simply recycled into the next reporting cycle.
Medicine expiry, unaccounted inventory, customs delays and regulatory barriers were all identified as systemic risks. Each carries its own consequence. Expiry wastes scarce product. Unaccounted inventory undermines planning. Regulatory barriers slow release. Customs delays compound all three.
The committee also examined the growing integration of NTD activities with other health campaigns. Coordinating medicines, financing, transport and data across programmes can extend reach, but it also introduces operational complexity. Shared logistics only work when responsibilities are explicit and data are synchronized across campaigns.
Transition planning for 2030 and beyond is already part of the supply chain debate
As the 2030 target approaches, WHO and partners are already discussing how countries should prepare for possible changes in donations and external financing. The Geneva meetings made clear that transition planning cannot wait for the final years of the decade.
Planning needs to cover forecasting, financing, procurement, regulatory and quality requirements, legal arrangements and advocacy together. Breaking those tasks apart invites delay. When they are handled as one continuum, countries can build a more durable path for access to quality-assured NTD medicines even if donor patterns or funding models shift.
The week ended with progress on the table and unresolved pressure points still visible. Customs clearance has improved in some settings, standard operating procedures are expanding and country-led coordination is gaining ground. Yet forecasting gaps, inventory blind spots, shipment delays and accountability problems remain embedded across the system, and those frictions will determine whether medicines reach communities on time as 2030 draws nearer.